The Trump administration has received more credit for lowering drug prices than the Biden administration, although it uses the Inflation Reduction Act program created under Biden.[1] The Trump administration has announced price cuts for 15 drugs, including popular GLP-1 drugs like Wego and Ozempic, which should save Medicare about $12 billion in net drug costs.[1][5] The prices of Ozempic and Wego dropped from $1,000 and $1,350 a month, respectively, to $350 when purchased through TrumpRx, a government-run website launched in October 2025.[3][5] The Trump administration achieves these prices through threats and collusion with pharmaceutical companies, which is less predictable than Biden's approach.[1] The Biden administration has announced price cuts of an estimated 22 percent for 10 drugs, while the Trump administration is achieving an estimated 36 percent reduction for 15 drugs.[1] It is unclear why the rebates provided through the Inflation Reduction Act are larger under Trump than under Biden.[1]